Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Local Treatment in Addition to Endocrine Therapy in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR): a Multicentre, Single -Arm, Phase 2 Trial

NCT03750396 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT03750396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03750396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Local Treatment in Addition to Endocrine Therapy in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR): a Multicentre, Single -Arm, Phase 2 Trial
Lead sponsor
Gangnam Severance Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2018
Completion date
July 31, 2025
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, estrogen receptor positive tumor, her2-negative tumor, recurrent breast cancer, stereotactic body radiotherapy, surgery